ASD Severity Levels and Legal Eligibility
The DSM-5 classifies autism spectrum disorder across three severity levels. Level 1 ASD (formerly Asperger's syndrome or high-functioning autism) describes individuals who require some support — they may attend mainstream school with accommodations, develop functional verbal communication, and achieve varying degrees of independence. Level 2 ASD describes individuals who require substantial support across multiple settings — limited verbal communication, significant behavioral challenges, and reduced capacity for independent living. Level 3 ASD describes individuals who require very substantial support — minimal or no functional speech, severe behavioral challenges, and the need for 24-hour supervision or residential placement. All three levels are eligible in the acetaminophen-autism litigation. The severity level affects the damages calculation: lifetime care costs for level 2 ASD exceed $1 million in most cases, and level 3 ASD lifetime care costs range from $2.4 million to $3.2 million based on JAMA Pediatrics 2020 research.
Evidence Needed for an ASD Claim
The two essential categories of evidence are prenatal exposure documentation and diagnostic records. For exposure: pharmacy records, prenatal OB records, and maternal recollection of Tylenol or generic acetaminophen use during pregnancy — any brand qualifies. For diagnosis: the formal evaluation report from a developmental pediatrician, child psychologist, or psychiatrist diagnosing ASD; IEP and 504 records from school documenting the educational impact; behavioral therapy records (ABA, speech, occupational therapy); and any neuropsychological testing. An autism diagnosis does not need to have been made early — many children receive formal ASD diagnoses at age 6, 8, or even in adolescence. The diagnosis simply must have been made before age 18.
Why California and Illinois Matter for ASD Families
Federal MDL-3043 was dismissed in August 2024 when Judge Cote excluded plaintiffs' causation experts. The Second Circuit heard the appeal on November 17, 2025. But ASD families do not need to wait for the appeal: California's Alameda County and Illinois's St. Clair, Madison, and Cook counties are actively handling ASD cases right now under the Frye admissibility standard. The 91-scientist Nature Reviews Endocrinology consensus statement (2021) provides strong support for Frye-standard general acceptance. Filing in state court now preserves your rights regardless of the Second Circuit's ruling.
Frequently Asked Questions
Related Pages
Tylenol Liver Damage Lawsuit
Acetaminophen — the active ingredient in Tylenol — is the leading cause of acute liver failure in the United States, responsible for approximately 56,000 emergency room visits, 26,000 hospitalizations, and nearly 500 deaths each year. Lawsuits allege that McNeil Consumer Healthcare and parent company Johnson & Johnson failed to adequately warn consumers about the narrow margin between a therapeutic dose and a potentially fatal overdose. Even doses only slightly above the recommended amount, especially when combined with alcohol use or taken across multiple acetaminophen-containing products, can cause catastrophic liver damage. If you or a loved one suffered acute liver failure, liver transplant, or death linked to acetaminophen use, you may be eligible for compensation. These liver damage claims are separate from the Tylenol autism/ADHD litigation — they involve direct injury to the person who took the medication.
Learn moreLearn moreLearn moreLearn moreLearn moreLearn moreLearn moreTylenol Autism Lawsuit Lawsuit
Acetaminophen — sold under the brand name Tylenol by Kenvue (formerly Johnson & Johnson) and as dozens of store-brand generics by Walmart, CVS, Walgreens, Target, Costco, Meijer, and others — was the most commonly used pain reliever during pregnancy in the United States for decades. Starting with a landmark 2018 American Journal of Epidemiology meta-analysis of 130,000 mother-child pairs, and culminating in a 2021 consensus statement signed by 91 scientists published in Nature Reviews Endocrinology, accumulating evidence linked prolonged prenatal acetaminophen exposure to significantly elevated risks of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). The federal multidistrict litigation, MDL-3043 (In re Acetaminophen — ASD/ADHD Products Liability Litigation) in the Southern District of New York, was dismissed in August 2024 after Judge Denise L. Cote excluded all plaintiffs' general causation experts under the Daubert standard. Critically, the Second Circuit Court of Appeals heard oral arguments on November 17, 2025 — and two of the three judges on the panel openly questioned whether Judge Cote acted too aggressively in excluding the expert testimony. A reversal by the Second Circuit could reinstate thousands of federal cases. Separately, California state courts (Alameda County) and Illinois state courts (St. Clair, Madison, and Cook counties) have active acetaminophen-autism cases proceeding under the Frye admissibility standard, which does not apply the same gatekeeping test that closed the federal MDL. Store-brand acetaminophen users have the same legal claims as Tylenol brand users — the failure-to-warn theory applies equally to Walmart's Equate brand, CVS Health brand, Walgreens brand, Costco Kirkland brand, and all other private-label acetaminophen products.
View full case overview